thelancet.com/journals/lanr...
‘…Biologics have come to the forefront as glucocorticoid-sparing agents. After the seminal GiACTA trial, tocilizumab is now recommended as a first-line therapy for giant cell arteritis in combination with a glucocorticoid taper.’ (Worth reading the embedded links.)
There’s a difference between Tocilizumab being recommended and actually being prescribed.